Archive | June, 2013

Aspirin May Fight Cancer by Slowing DNA Damage

Researchers hypothesized that NSAIDs modulate clonal evolution by reducing SGA acquisition rate. Researchers  evaluated thirteen individuals with BE. Eleven had not used NSAIDs for 6.2±3.5 (mean±standard deviation) years and then began using NSAIDs for 5.6±2.7 years, whereas two had used NSAIDs for 3.3±1.4 years and then discontinued use for 7.9±0.7 years. 161 BE biopsies, collected […]

Continue Reading

Entrepreneurial mothers push hard

Mumpreneurs? To Americans, I assume the word is mompreneurs and to English northerners mampreneurs. Either way, the phenomenon of entrepreneur mothers is nothing new. It’s certainly not something that emerged during the web 2.0 explosion when mothers running small businesses and looking after growing kids were keen to market themselves on Twitter, Facebook and in […]

Continue Reading

Flamel Technologies Announces FDA Approval of Bloxiverz

Flamel Technologies today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for Bloxiverz ( neostigmine (see structure below) methylsulfate), a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch Bloxiverz in […]

Continue Reading

What do you do if you’ve got osteoarthritis of the knee?

Film director Baz Luhrmann made a spoof graduation speech famous with his hit “Everybody’s Free (To Wear Sunscreen)” back in 1999. At the time, I wasn’t particularly worried about the line in that track: “Be kind to your knees, you’ll miss them when they’re gone.” But, you get older, knees become more of a focus, […]

Continue Reading

Introducing BiologicPatentWatch: Biotechnology Industry Competitive Intelligence

After months of development, BiologicPatentWatch.com is live. Building on the framework of DrugPatentWatch, BiologicPatentWatch provides comprehensive details on FDA approved biologic drugs, developers and patents. The integrated databases allow both freeform searching and dynamic browsing, making it easy to find information on drug patents both in the US and internationally, Orphan Drug Status, trends in […]

Continue Reading

Arbor Pharmaceuticals Announces FDA Approval of Nymalize

We know that, Nimodipine (marketed by Bayer as Nimotop) is a dihydropyridine calcium channel blocker originally developed for the treatment of high blood pressure. It is not frequently used for this indication, but has shown good results in preventing a major complication of subarachnoid hemorrhage (a form of cerebral hemorrhage) termed vasospasm; this is now […]

Continue Reading